Clinical trials: ASV
Hepatitis C Virus Infection
Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus Trials
The purpose of this study is to provide anti-hepatitis C virus drugs to patients who received placebo + peginterferon alfa-2a + ribavirin in prior Bristol-Myers Squibb (BMS) studies and determine whether addition of these drugs…
- Trial name
- NCT01428063
- Testing
- Daclatasvir, Asunaprevir, Pegylated interferon alfa-2a
- Where
- 106 sites in United States, Argentina and 17 more
- Volunteers
- 276 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial
The primary purpose of this study is to determine whether the hepatitis C virus continues to remain unable to be detected in subjects who were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) and…
- Trial name
- NCT01492504
- Testing
- Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)
- Where
- 161 sites in United States, Argentina and 17 more
- Volunteers
- 1,850 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults
The primary objective of the study is to determine the number of adverse events (AEs) reported by chronic hepatitis C (CHC) patients receiving at least 1 dose of daclatasvir (DCV) and asunaprevir (ASV) at the 2 sentinel sites and…
- Trial name
- NCT03208322
- Testing
- Non-Interventional
- Where
- 2 sites in Mexico
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Infection
Study of Drug Combination on Pharmacokinetics in Healthy Volunteers
The purpose of this study is to assess the effect of Daclatasvir, Asunaprevir, and BMS-791325 on the pharmacokinetics of selective serotonin reuptake inhibitors.
- Trial name
- NCT02175602
- Testing
- Escitalopram, Sertraline, DCV 3DAA FDC
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus Genotype 4 Infection
Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)
Success rates, after retreatment with Peg-Interferon/Ribavirin bitherapy, in patients infected with HCV (hepatitis C virus) genotype 4 and non-responders to a first standard treatment, are disappointing.
- Trial name
- NCT02107365
- Testing
- Asunaprevir, Daclatasvir, Ribavirin
- Where
- 25 sites in France
- Volunteers
- 60 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Obstructive Sleep Apnea, Central Sleep Apnea (Diagnosis)
Effectiveness of Adaptive Servoventilation (ASV) in Patients With Central Sleep Apnea Due to Chronic Opioid Use
Prospective, randomized, blinded, cross-over study assessing the effectiveness of adaptive servo-ventilation (ASV) in treating patients who have obstructive sleep apnea (OSA) complicated by central sleep apnea (CSA) due to the…
- Conditions
- Obstructive Sleep Apnea, Central Sleep Apnea (Diagnosis), Chronic Opioid Use
- Trial name
- NCT01462084
- Testing
- Adaptive servo-ventilation (ASV), Bi-Level PAP
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- ResMed
Hepatitis C
Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea
The primary objective of this study is to describe the safety of the combination of Daklinza (daclatasvir) and Sunvepra (asunaprevir) when used for the treatment of chronic hepatitis C (CHC) genotype 1b patients in real-life…
- Trial name
- NCT02727933
- Where
- South Korea
- Volunteers
- 1,941 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C Virus Infection
UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C
The purpose of this study is to demonstrate that the proportion of treatment-naive non-cirrhotic subjects with Genotype (GT)-1b treated with Daclatasvir (DCV)/Asunaprevir (ASV)/BMS-791325 who achieve Sustained Virologic response…
- Trial name
- NCT02123654
- Testing
- Daclatasvir, Asunaprevir, DCV 3DAA
- Where
- 35 sites in Japan
- Volunteers
- 297 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual
Patients with chronic hepatitis genotype 1b, who are intolerant or ineligible to Interferon alfa therapy with or without Ribavirin, will be treated for 24 weeks with Daclatasvir (DCV) Dual regimen (= Daclatasvir + Asunaprevir)…
- Trial name
- NCT01995266
- Testing
- Asunaprevir, Daclatasvir
- Where
- 38 sites in China, South Korea and 1 more
- Volunteers
- 218 people
- Sponsor
- Bristol-Myers Squibb
Heart Failure With Normal Ejection Fraction, Sleep Apnea
Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study
This study is designed to demonstrate feasibility of study conduct and that acceptable adherence to adaptive servo-ventilation (ASV) therapy can be achieved in recently hospitalized HFpEF patients with moderate to severe sleep…
- Trial name
- CAT-PEF (NCT03195660)
- Testing
- ASV Therapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 6 people
- Sponsor
- ResMed
Hepatitis C Infection
A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir
Grps 1, 2, 3 "This study will be testing the performance of ASV and DCV pediatric chewable tablets. Grp #4 The purpose of this group is to support the marketing authorization of a DCV 90-mg tablet
- Trial name
- NCT02323594
- Testing
- Daclatasvir, Asunaprevir
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Burn, War-Related Injuries
ASV and Targeted Fluid Resuscitation in Severe Burns
This prospective cohort study will evaluate the use of Adaptive Support Ventilation (ASV) together with targeted fluid resuscitation in adult patients with severe burn injuries requiring mechanical ventilation in the intensive…
- Conditions
- Burn, War-Related Injuries, Mechanical Ventilation, Infusion Fluid
- Trial name
- BURN-ASV/TFR (NCT07689097)
- Where
- Ukraine
- Volunteers
- 100 people
- Sponsor
- Ukrainian Society of Regional Anesthesia and Pain Therapy
Chronic Hepatitis C
Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care
The purpose of this study is to determine whether BMS-650032 and BMS-790052 in combination alone, together with Ribavirin, or together with Interferon and Ribavirin are effective in the treatment of Hepatitis C in patients who…
- Trial name
- NCT01012895
- Testing
- BMS-790052, BMS-650032, Pegylated-interferon alfa-2a
- Where
- 18 sites in United States, France and 1 more
- Volunteers
- 215 people
- Sponsor
- Bristol-Myers Squibb
Insomnia, Insomnia (Moderate)
ASV Therapy for Insomnia
This will be a single center, prospective study designed to evaluate the effect of adaptive servo ventilation therapy on insomnia severity among patients with moderate to severe chronic insomnia.
- Trial name
- NCT07011966
- Testing
- ASV therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- ResMed
Acute Respiratory Failure, Coma
EASiVENT Study Comparing INTELLiVENT-ASV vs Non Automated Ventilation in Adult ICU Patients
The purpose of the study is to assess the safety and efficacy of INTELLiVENT-ASV (Adaptive Support Ventilation) in adult ICU patients comparing to non automated ventilation.
- Conditions
- Acute Respiratory Failure, Coma, Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT04400643
- Testing
- INTELLiVENT-ASV, Non-automated ventilation
- Where
- Portugal
- Volunteers
- 62 people
- Sponsor
- Hamilton Medical AG
Mechanical Ventilation Complication, Intensive Care Unit
INTELLiVENT-ASV Using Mainstream Versus Sidestream End-Tidal CO2 Monitoring
Background INTELLiVENT-ASV, an automated closed-loop mode of mechanical ventilation, available on Hamilton ventilators for clinical use, uses mainstream end-tidal CO2 (etCO2) monitoring to adjust minute ventilation.
- Conditions
- Mechanical Ventilation Complication, Intensive Care Unit, Postoperative Care
- Trial name
- INTELLiSTREAM (NCT04599491)
- Testing
- Sidestream capnography using the 'Respironics LoFlo Sidestream CO2 Module', Mainstream capnography using the 'Respironics Capnostat 5 Mainstream CO2 sensor'
- Where
- Netherlands
- Volunteers
- 72 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Insomnia, Sleep-Disordered Breathing
CPAP vs ASV for Insomnia
The study will determine which of two different types of positive airway pressure (PAP therapy) modes are more effective in reducing sleep breathing events in chronic insomnia patients and in decreasing insomnia severity.
- Trial name
- P2P (NCT02365064)
- Testing
- AirCurve 10 ASV
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- ResMed
Ventilation Therapy; Complications
A Comparison of Intellivent-ASV Mode With Conventional Modes in Patients With BMI >35
compare effects of intellectual mode (in our case it will be Intellivent - ASV -) with conventional ventilation modes after uncomplicated cardiac surgery in patients with body mass index >35
- Trial name
- NCT04973917
- Testing
- respiratory support
- Where
- Russia
- Volunteers
- 32 people
- Sponsor
- Petrovsky National Research Centre of Surgery
Hepatitis C
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)
The purpose of the study is to determine whether the combination of Daclatasvir (DCV), Asunaprevir (ASV), BMS-791325 and Sofosbuvir is effective and safe in treating Hepatitis-C virus.
- Trial name
- FOURward (NCT02175966)
- Testing
- DCV/ASV/BMS-791325, Ribavirin, Sofosbuvir
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325
The purpose of this study is to assess the effect of DCV/ASV/BMS-791325 fixed dose combination (FDC) + 75mg BMS-791325 on the Pharmacokinetics (PK) of the oral contraceptive agent.
- Trial name
- NCT02103569
- Testing
- FDC of Daclatasvir, Asunaprevir and BMS-791325, FDC of Norethindrone and Ethinyl Estradiol, BMS-791325
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb